Gary Nachman
Stock Analyst at Raymond James
(2.99)
# 1,261
Out of 5,182 analysts
101
Total ratings
58.9%
Success rate
4.88%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Reiterates: Strong Buy | $85 → $89 | $74.33 | +19.74% | 4 | Oct 30, 2025 | |
| BLCO Bausch + Lomb | Reiterates: Outperform | $18 → $19 | $16.34 | +16.28% | 2 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Reiterates: Outperform | $40 → $50 | $9.61 | +420.29% | 3 | Oct 20, 2025 | |
| ABBV AbbVie | Reiterates: Outperform | $236 → $250 | $206.69 | +20.95% | 17 | Oct 17, 2025 | |
| AMGN Amgen | Assumes: Market Perform | n/a | $342.57 | - | 2 | Sep 3, 2025 | |
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $2.40 | +733.33% | 2 | Aug 13, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $11.52 | +143.06% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $330.34 | -9.79% | 7 | Nov 1, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $3.23 | +519.20% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $22.27 | +66.14% | 13 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $30 | $48.81 | -38.54% | 5 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $4.09 | +71.15% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $186.85 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $12.35 | -67.61% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $11.25 | +166.67% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $3.39 | +843.95% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $13.41 | +4.40% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $75 | $9.60 | +681.25% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $29.82 | -66.47% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $27.36 | +9.65% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $4.24 | +17,588.68% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $5.41 | +47.87% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $20.58 | +2.04% | 5 | May 11, 2020 |
Ionis Pharmaceuticals
Oct 30, 2025
Reiterates: Strong Buy
Price Target: $85 → $89
Current: $74.33
Upside: +19.74%
Bausch + Lomb
Oct 30, 2025
Reiterates: Outperform
Price Target: $18 → $19
Current: $16.34
Upside: +16.28%
LENZ Therapeutics
Oct 20, 2025
Reiterates: Outperform
Price Target: $40 → $50
Current: $9.61
Upside: +420.29%
AbbVie
Oct 17, 2025
Reiterates: Outperform
Price Target: $236 → $250
Current: $206.69
Upside: +20.95%
Amgen
Sep 3, 2025
Assumes: Market Perform
Price Target: n/a
Current: $342.57
Upside: -
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $2.40
Upside: +733.33%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $11.52
Upside: +143.06%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $330.34
Upside: -9.79%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $3.23
Upside: +519.20%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $22.27
Upside: +66.14%
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $48.81
Upside: -38.54%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $4.09
Upside: +71.15%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $186.85
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $12.35
Upside: -67.61%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $11.25
Upside: +166.67%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $3.39
Upside: +843.95%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $13.41
Upside: +4.40%
Nov 14, 2022
Maintains: Outperform
Price Target: $90 → $75
Current: $9.60
Upside: +681.25%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $29.82
Upside: -66.47%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $27.36
Upside: +9.65%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $4.24
Upside: +17,588.68%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $5.41
Upside: +47.87%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $20.58
Upside: +2.04%